Glenmark's Double Recall: Addressing Manufacturing Defects

Glenmark Pharmaceuticals is recalling two products in the US due to manufacturing defects. Ryaltris nasal spray faces a Class II recall due to a clogged dip tube, while Ciclopirox Gel is subject to a Class III recall. India remains a major supplier of generic medicines globally.

Glenmark Pharmaceuticals is facing two significant recalls in the United States owing to manufacturing defects, as per information from the US Food and Drug Administration (USFDA). The New Jersey-based branch of the Mumbai-headquartered company is pulling back 45,504 bottles of its Ryaltris nasal spray.

This recall, categorized as Class II, stems from a defective delivery system where a clogged dip tube hinders its functionality. The recall was initiated on September 24. In a separate recall, 11,568 tubes of Ciclopirox Gel, manufactured in Goa, are being recalled due to defective containers, resulting in broken seals. This is designated a Class III recall.

While the Ryaltris situation poses minimal risk of severe health outcomes, Glenmark's actions reflect its commitment to safety amidst its ranking as a world leader in generic medication supply, contributing over 20% of global demand, with significant exports to the US, Japan, and Europe.